Follow

A new study published in PLOS Global Public Health shows that a short, all-oral, 6-month treatment regimen for drug-resistant can save national governments up to US$740 million annually. This regimen will be included in the new World Health Organization (WHO) guidelines for the treatment of DR-TB, a form of the disease which impacts nearly half a million people each year. Find out more about how the cost of implementing this therapy is potentially 40-90% less expensive than current regimens: journals.plos.org/globalpublic

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.